Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
As of today, Regeneron(REGN) shares are valued at $780.09. The company's market cap stands at 82.03B, with a P/E ratio of 18.68 and a dividend yield of 33.8%.
On 2025-12-01, Regeneron(REGN) stock opened at $784.70, reached a high of —, and a low of —.
The Regeneron(REGN)'s current trading volume is 0, compared to an average daily volume of 1.27M.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $800.99 and a 52-week low of $476.49.
REGN News
Key Points Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulat...
Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent (dupilumab) for the treatment of moderate-to-severe chron...
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Analyst ratings
70%
of 30 ratingsMore REGN News
Regeneron (REGN) and Sanofi (SNY) announced that the European Commission has approved Dupixent for the treatment of moderate-to-severe chronic spontaneous urtic...
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a...
How bad were things for the S&P 500 Index ($SPX) on Thursday, Nov. 20? Not quite as bad as you might think. I’ve been writing here on Barchart for months, lame...
In recent trading, shares of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $696.42, changing ha...